Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

4.0K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.0K
Adult Stem Cells01:33

Adult Stem Cells

33.4K
Stem cells are undifferentiated cells that divide and produce more stem cells or progenitor cells that differentiate into mature, specialized cell types. All the cells in the body are generated from stem cells in the early embryo, but small populations of stem cells are also present in many adult tissues including the bone marrow, brain, skin, and gut. These adult stem cells typically produce the various cell types found in that tissue—to replace cells that are damaged or to continuously...
33.4K
Embryonic Stem Cells00:58

Embryonic Stem Cells

32.1K
Embryonic stem (ES) cells are undifferentiated pluripotent cells, meaning they can produce any cell type in the body. This gives them tremendous potential in science and medicine since they can generate specific cell types for use in research or to replace body cells lost due to damage or disease.
32.1K
Embryonic Stem Cells00:57

Embryonic Stem Cells

4.8K
Embryonic stem (ES) cells were first discovered in mice in 1981 by Martin Evans. In 1998, James Thomson identified a method to isolate embryonic stem cells from humans. Human embryonic stem cells (hESCs) are obtained from 3-5 day old embryos that remain unused after an in vitro fertilization procedure.
ES cells are grown in a culture medium where they can divide indefinitely, creating ES cell lines. Under certain conditions, ES cells can differentiate, either spontaneously into a variety of...
4.8K
Induced Pluripotent Stem Cells01:13

Induced Pluripotent Stem Cells

27.3K
Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore...
27.3K
Distinctive Features of Adult Stem Cells vs Cancer Stem Cells01:18

Distinctive Features of Adult Stem Cells vs Cancer Stem Cells

4.5K
A stem cell is an unspecialized cell that can divide without limit as needed and can, under specific conditions, differentiate into specialized cells.
Adult stem cells
Adult stem cells are tissue-specific; hence, they divide to develop the tissue from which they originate. One type of adult stem cell is the epithelial stem cell, which gives rise to the keratinocytes in the multiple layers of epithelial cells in the epidermis of the skin. Adult bone marrow has three distinct types of stem cells:...
4.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dynamics of IDH1/2 mutated clones in acute myeloid leukemia challenge their use as universal MRD markers.

Blood cancer journal·2026
Same author

Clonal Dynamics of FLT3-ITD from Diagnosis to Relapse: Ultra-Sensitive Patient-Specific Monitoring by ddPCR.

International journal of molecular sciences·2026
Same author

Tips and tricks in cryopreservation of hematopoietic stem cells: critical points to keep under control.

Cytotherapy·2026
Same author

Real life use of ravulizumab in Italian patients with paroxysmal nocturnal hemoglobinuria: evidence from the REACTION observational study.

Annals of hematology·2026
Same author

Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study.

British journal of haematology·2025
Same author

Unveiling Cryptic <i>BCR-ABL1</i> Rearrangements: Diagnostic Challenges and Clinical Impact in Myeloid Malignancies.

International journal of molecular sciences·2025

Related Experiment Video

Updated: Jan 24, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.7K

Chronic myeloid leukemia stem cells.

Mohammad Houshmand1, Giorgia Simonetti2, Paola Circosta1

  • 1Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.

Leukemia
|May 26, 2019
PubMed
Summary

Identifying the chronic myeloid leukemia stem cell (LSC) is challenging due to assay variability and unstable features. This review examines LSC biology and TKI targeting for potential CML cure.

More Related Videos

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.4K
Flow Cytometric Analysis of Mitochondrial Reactive Oxygen Species in Murine Hematopoietic Stem and Progenitor Cells and MLL-AF9 Driven Leukemia
09:44

Flow Cytometric Analysis of Mitochondrial Reactive Oxygen Species in Murine Hematopoietic Stem and Progenitor Cells and MLL-AF9 Driven Leukemia

Published on: September 5, 2019

7.8K

Related Experiment Videos

Last Updated: Jan 24, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.7K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.4K
Flow Cytometric Analysis of Mitochondrial Reactive Oxygen Species in Murine Hematopoietic Stem and Progenitor Cells and MLL-AF9 Driven Leukemia
09:44

Flow Cytometric Analysis of Mitochondrial Reactive Oxygen Species in Murine Hematopoietic Stem and Progenitor Cells and MLL-AF9 Driven Leukemia

Published on: September 5, 2019

7.8K

Area of Science:

  • Hematology
  • Cancer Biology
  • Stem Cell Research

Background:

  • Chronic myeloid leukemia (CML) originates from a specific leukemia stem cell (LSC) harboring the BCRABL1 fusion gene.
  • Current operational definitions of CML LSCs rely on in vitro or in vivo assays in immune-deficient mice, which can yield discordant results.
  • The assumption of stable biological features of CML LSCs is unproven, complicating precise identification.

Purpose of the Study:

  • To review the biological characteristics of CML LSCs as defined by current assays.
  • To evaluate the susceptibility of CML LSCs to tyrosine kinase inhibitors (TKIs) and other therapeutic agents.
  • To discuss the necessity of CML LSC elimination for achieving therapy-free remission or a cure for CML.

Main Methods:

  • Review of existing literature on CML LSC biology and assays.
  • Analysis of studies investigating TKI efficacy against CML LSCs.
  • Discussion of therapeutic strategies targeting CML LSCs.

Main Results:

  • Operational definitions of CML LSCs can be inconsistent, making definitive identification difficult.
  • The susceptibility of CML LSCs to TKIs and other drugs remains an area of active investigation.
  • The role of LSC elimination in achieving durable CML remission or cure is not yet fully established.

Conclusions:

  • Accurate and precise identification of CML LSCs is hampered by assay limitations and potential instability of LSC features.
  • Further research is needed to clarify the susceptibility of CML LSCs to targeted therapies.
  • Determining the necessity of LSC eradication is crucial for advancing CML treatment towards a definitive cure.